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Abstract
Prostate cancer (CaP) is the most frequently diagnosed malignant tumour and the second leading cause of cancer deaths in American
men. One of the most troubling aspects of this disease is that, after androgen ablation therapy, androgen-dependent cancer cells
inevitably progress to an androgen-independent status, for which no effective treatment has yet been developed. To date, the mecha-
nisms that underlie the occurrence and progression of CaP remain largely unknown. Recent studies suggest that microRNAs (miRNAs)
are involved in human tumourigenesis. Some aberrantly expressed miRNAs have been discovered in CaP cell lines, xenografts and clin-
ical tissues and these CaP-related miRNAs may play critical roles in the pathogenesis of CaP. This review provides an overview of cur-
rent findings about aberrantly expressed miRNAs in CaP. Although a number of CaP-related miRNAs were discovered, to date, only five
are characterized for their functionalities: three as oncogenes and two as tumour suppressors. To understand the mechanisms of miRNA
action as oncogenes or tumour suppressors, mRNA targets of miRNAs were characterized. Oncogenic miRNAs down-regulate the
expression of apoptosis-related genes, and tumour suppressor miRNAs target the proliferation-related genes. Importantly, there is evi-
dence that CaP-related miRNAs are regulated through androgen signalling and that this regulation may contribute to the development
of androgen independence. Due to the oncogenic or tumour-suppressive properties of CaP-related miRNAs, they are highly likely to be
of clinical use first as biomarkers but more importantly as therapeutic targets for prostate cancer treatment in the near future.
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Introduction
In the past, most studies of the regulation of gene expression have
focused mainly upon transcriptional activity. Over the last few
years, microRNA (miRNA)-mediated post-transcriptional regula-
tion of protein-coding genes has emerged as a promising area of
research. This regulation provides the cell with a more precise,
immediate and energy-efficient mechanism for controlling the
expression of proteins. This occurs since it can mediate rapid
changes in protein synthesis without the need for transcriptional
activation and subsequent mRNA processing steps [1]. The first
miRNA was discovered in 1993 by Lee et al. [2] who observed that
a 22-base RNA (lin-4) could bind to the 3-untranslated region
(3-UTR) of lin-14 mRNA and repress its translation in
Caenorhabditis elegans. This discovery engendered scant atten-
tion. It was 7 years later that a second 22-base RNA let-7 was
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identified in C. elegans by another group [3]. Similarly to lin-4, let-
7 recognized sequences present in the 3-UTR of lin-41 mRNA and
repressed Lin-41 protein level. This time scientists immediately
realized that these small RNA molecules play an important role in
the regulation of gene expression. Identification and functional
studies of miRNAs extend rapidly from C. elegans to other species
including human. To date, nearly 500 human miRNAs have been
identified, while up to ~1000 miRNAs have been postulated to
exist [4, 5]. In this review, after briefly describing the biogenesis
of miRNAs and their role in human cancer, we summarize what is
currently known about the involvement of miRNAs in prostate
cancer (CaP).
miRNAs and human cancer
miRNAs are a class of naturally occurring, small non-coding RNAs
that function in the negative regulation of gene expression. The
maturation of miRNAs proceeds in a step-wise enzymatic course [6].
In mammalian cells, miRNAs are initially transcribed in the nucleus
as long primary miRNA (pri-miRNA) transcripts that are subse-
quently processed to produce hairpin-like miRNA precursors (pre-
miRNAs) that range in length from 60 to 110 nucleotides (nt). The
pre-miRNAs are transported to the cytoplasm where they are fur-
ther processed into ~22-nt duplexes of mature miRNA strand and
an miRNA passenger strand, with 2-nt overhangs at the 3 termi-
ni [7]. The mature miRNA strand is incorporated into the ribonu-
cleoprotein complex RISC (RNA-induced silencing complex),
while the passenger strand is degraded. The mature miRNA binds
to its target mRNA(s) by complete or partial complementarity of
the 5-end nucleotides 2–8 or 2–7 (seed sequences) with a bind-
ing site in the 3-UTR of the target transcripts [8–11]. This subse-
quently results in either direct cleavage of the targeted mRNAs by
nucleases within the RISC or inhibition of translation [12]. The
characteristically short seed sequence permits a single miRNA to
act on multiple target sites. Bioinformatic analyses have predicted
that each miRNA recognizes on average about 100–200 different
mRNA targets [5, 13] and thus miRNAs can mediate the regula-
tion of a considerable number of protein-coding genes [14].
Additionally, the 3-UTR of a given mRNA may contain binding
sites for various miRNAs. As a result, miRNAs are involved in
almost all cellular processes in mammals, including cell prolifera-
tion, differentiation, stress response, apoptosis, immunity and
transcriptional regulation [5].
There is now abundant evidence that aberrant expression of
miRNAs occurs in diverse types of human cancer and in different
stages of disease progression [15, 16]. Moreover, several miRNAs
have recently been found to promote cell survival and tumour
growth [17–19]. Therefore, miRNAs may play a critical role in the
pathogenesis of human cancer. Studies have shown that some
miRNAs can be overexpressed or down-regulated in cancer cells
[20]. Overexpression of miRNAs can be due to amplification,
demethylation in the promoter regions of miRNAs or deregulation
of a transcription factor, while down-regulation may be due to
deletions, epigenetic silencing or loss of the expression of neces-
sary transcription factors [21]. Overexpressed miRNAs may act as
oncogenes since they can repress tumour suppressor or apopto-
sis-related genes. An example is miR-155 that is highly expressed
in lymphoma. Transgenic overexpression of miR-155 targeted to
B cells caused the development of B-cell malignancies having fea-
tures of lymphoblastic leukaemia(high-grade lymphoma, thereby
indicating that deregulation of a single miRNA can promote malig-
nant transformation [22]. In contrast, down-regulated miRNAs
may function as tumour-suppressors since they usually suppress
the expression of oncogenes or proliferation-related genes. For
instance, deletion or down-regulation of miR-15 and miR-16 in
chronic lymphocytic leukaemia causes overexpression of the anti-
apoptosis molecule Bcl2 [23]. In addition, a given miRNA can be
a tumour suppressor if its mRNA targets are oncogenes in one
cancer cell type. It can also function as an oncogene if its targets
are tumour suppressors in a different tumour cell type. Therefore,
if a miRNA functions as a tumour suppressor or oncogene, it
depends on its targets in specific cancer tissue [24, 25]. Although
many miRNAs have been found to be significantly differentially
expressed in different cancer types, to date, only a few have been
well characterized for their functional significance. In order to elu-
cidate the contribution of each miRNA to cancer pathogenesis, a
large body of work needs to be completed.
Aberrant expression of miRNAs in
prostate cancer
CaP is the most frequently diagnosed malignant tumour and the
second leading cause of cancer deaths in American men [26].
Retrospective studies suggest that by age 80, more than half of all
American men have some cancerous cells in their prostate [27].
Most of these men are asymptomatic and clinical treatment is not
needed. In contrast, some cancer cells indeed exhibit aggressive
behaviour characterized by possessing a more poorly differentiat-
ed phenotype, heightened proliferative index and increased motil-
ity and invasiveness. These have the propensity to quickly spread
locally and metastasize. Androgen ablation therapy remains the
most effective treatment for disseminated disease. However, this
treatment is not curative since it results in only a temporary
tumour regression. Inevitably, some cancer cells become resistant
to hormonal ablation, and relapsed tumour growth emerges usu-
ally within 12–18 months. These have been referred to as ablation-
resistant, hormone-refractory, or androgen-independent (AI) CaPs
[28]. The mechanisms underlying the development and progres-
sion of CaP are complex and largely ill-defined. Combined with the
heterogeneous nature of the disease, this has impeded the devel-
opment of effective therapies. Since miRNAs have powerful func-
tions in gene regulation, it is anticipated that identification of
CaP-related miRNAs can shed light on understanding the molecu-
lar alterations associated with the pathogenesis of CaP.
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Aberrant expression of several miRNAs has been found in
CaP cells. In an early study, Jiang et al. [29] analysed the abun-
dances of selected miRNAs in CaP cell lines using real-time PCR.
They found that AI cell lines exhibited 4-fold increased expres-
sion of miR-100 and androgen-dependent (AD) LNCaP cells had
53-fold increased levels of let-7c, relative to control cells. In
addition, Lee et al. [30] observed that PC3 cells highly expressed
miR-125b. Kore et al. [31] employed locked nucleic acids (LNA)-
labelled miRNA probes to detect let-7c expression in human CaP
samples. They found that let-7c was clearly present in CaP cells.
Recently, Lin et al. [32] compared miRNA expression profiles
between AI and AD CaP cells. Three miRNAs (miR-184, miR-361
and miR-424) were significantly up-regulated, and eight (miR-
19b, miR-29b, miR-128b, miR-146a, miR-146b, miR-221, miR-
222 and miR-663) were down-regulated in AI cell lines relative
to AD cell lines. In order to understand the role of miRNAs in
CaP, we recently used Northern blot analysis to examine the
abundance of 11 miRNAs in seven CaP cell lines and two immor-
talized, non-malignant prostate epithelial cell lines. When com-
pared to non-malignant prostate cells, most CaP cell lines had
increased expression of miR-125b, miR-92, miR-191, miR-
106a, miR-145 and miR-21. Furthermore, androgen receptor
(AR)-positive cell lines expressed approximately 4-fold increase
in let-7c and 3- to 5-fold increase in miR-125b compared to AR-
negative ones. Additionally, when compared to parental cells, AI
LNCaP sublines exhibited reduced miR-92 and miR-106a
expression and elevated levels of miR-125b, miR-16, miR-21,
miR-30c and miR-100. These findings suggest that: (i ) these
aberrantly expressed miRNAs may contribute to prostatic
tumourigenesis; (ii ) the miRNAs differentially expressed in AD
and AI CaP cells are associated with androgen independence and
(iii ) the AR may regulate the expression of a subset of miRNAs
in CaP [33].
Global miRNA microarray profiling is a powerful technique to
investigate alterations in miRNAs in human cancer. This
approach enables the simultaneous analysis of the entire miRNA
expression repertoire of a particular sample in a single assay.
Furthermore, the uniform small size of miRNAs and their probes
contributes to reducing hybridization-caused variations that can
be encountered in mRNA microarray studies [34]. However, the
lack of comparability and low accuracy of the derived data have
been a major limitation of miRNA microarray studies [35]. Thus,
the aberrantly expressed miRNAs detected by microarray have to
be validated by using other techniques, such as Northern blot
analysis, real-time PCR or in situ hybridization (ISH). Recently,
three groups investigated the expression of miRNAs in clinical
CaP samples using miRNA microarray analysis. Volinia et al.
[20] examined the differential expression of 228 miRNAs in 56
CaP and 7 benign prostatic hyperplasia (BPH) tissues and iden-
tified 42 differentially expressed miRNAs with 36 (84%) being
up-regulated and six (14%) down-regulated in CaP samples.
Ozen et al. [36] analysed expression of 480 human miRNAs in 
10 BPHs and 16 clinical CaP tissues. They found that 76 (89%)
of 85 miRNAs were significantly down-regulated while only 
9 (11%) miRNAs were up-regulated in CaP samples. To identify
the miRNA signature specific for CaP, Porkka et al. [37] analysed
the miRNA expression profiling of 319 miRNAs in 4 BPHs and 
9 CaP samples, and detected 50 differentially expressed
miRNAs. Of these, 36 (72%) showed down-regulation and 14
(28%) up-regulation. Although these differentially expressed
miRNAs need to be validated, these investigators are in agree-
ment that aberrantly expressed miRNAs are associated with the
occurrence of CaP. However, these previous profiling studies
presented conflicting results. For example, a comparison of two
miRNA profiles in which the differentially expressed miRNAs are
available [20, 37] revealed that, of 12 differentially expressed
miRNAs reported in the two studies, only three (let-7a, miR-184
and miR-198) display identical, while nine miRNAs (let-7d, miR-
16, miR-26a, miR-27a, miR-29a, miR-29b, miR-30c, miR-92
and miR-195) exhibit a reverse differential expression (Table 1).
Although many factors can cause this disagreement, including
the lack of comparability and low accuracy as described above,
one of the major reasons may be contamination of CaP cells with
adjacent benign tissue and/or stromal cells, including fibrob-
lasts, smooth muscle cells and endothelial cells. In two profiling
studies [36, 37], for example, CaP samples contain up to 40%
benign cells. Since benign prostate cells also express miRNAs to
different extends, the results obtained from such samples would
not reflect the true levels of CaP-related miRNAs. Therefore,
accurate microarray analysis of miRNA expression profiles in
clinical CaP samples is not trivial and remains a significant chal-
lenge. The use of laser-capture microdissection (LCM) to enrich
for the CaP cells from clinical CaP samples should be helpful in
overcoming this problem.
Biological function of prostate 
cancer-related miRNAs
The initiation and progression of CaP is a complex biological
process involving multiple biochemical and genetic factors. Like
other human cancer types, the inactivation of tumour suppres-
sor genes and the activation of oncogenes may be major contrib-
utors to this disease. Since miRNAs function as oncogenes
(onco-miRNAs) or tumour suppressors (ts-miRNAs) [9, 21, 25],
altered expression of miRNAs may contribute to prostatic malig-
nant transformation and subsequent progression to androgen
independence. As described above, some CaP-related miRNAs
have been identified, but the biological significance of a majority
of these miRNAs remains unknown. Therefore, functional char-
acterization of these miRNAs with respect to their abilities to
mediate a gain of oncogenic activity or loss of tumour suppres-
sor function is urgently needed. Recently, several miRNAs were
reported to be either oncogenic or tumour suppressive, and
aberrant expression of these miRNAs promoted the proliferation
of CaP cells.
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miR-20a
The miR-17-92 cluster resides on chromosome 13 and compris-
es seven miRNAs (miR-17-5p, miR-17-3p, miR-18a, miR-19a,
miR-20a, miR-19b-1 and miR-92-1). A previous study demon-
strated that this miRNA cluster could modulate tumour formation
and functions as oncogenes [38]. Since miR-20a from this cluster
is overexpressed in clinical CaP samples [20], Sylvestre et al. [39]
examined the biological impact of miR-20a activity on apoptosis in
CaP cells. In that study, PC3 cells were transfected with anti-miR-
20a and then treated with doxorubicin, a DNA damaging agent that
induces apoptosis in PC3 cells. Repression of miR-20a activity
with anti-miR-20a resulted in a 50% increase in cell death com-
pared to PC3 cells treated with a scramble control. Conversely,
overexpression of miR-20a mediated a 2-fold reduction in cell
death and an approximately 4-fold increase in colony formation in
doxorubicin-treated PC3 cells relative to controls. These results
implicated miR-20a as being oncogenic via its anti-apoptotic func-
tion in CaP cells.
miR-125b 
Up-regulation of miR-125b was observed in PC3 [30], in LNCaP
[33, 37], LNCaP AI sublines [33, 37] and in a subset of clinical CaP
samples [33, 36]. In a previous study, miR-125b was found to be
critical for the proliferation of PC3 cells [30]. We recently report-
ed that androgen-independent LNCaP-cds cells markedly overex-
pressed miR-125b compared to parental LNCaP cells, suggesting
that miR-125b contributes to the progression of CaP. To test the
hypothesis, miR-125b levels were elevated in three CaP cell lines
by transfection with chemically modified, synthetic miR-125b.
Table 1 Deregulated miRNAs in clinical CaP samples
Volinia et al. [20] Porkka et al. [37]
Up-regulation Down-regulation Up-regulation Down-regulation
(36 miRNAs) (6 miRNA) (14 miRNAs) (36 miRNAs)
let-7d* miR-106a let-7a** miR-202 let-7a** let-7f
let-7i miR-124a miR-24 miR-210 let-7b miR-19b
miR-16* miR-135 miR-29a miR-296 let-7c miR-22
miR-17-5p miR-146 miR-128a miR-320 let-7d* miR-26b
miR-20a miR-148 miR-149 miR-370 let-7g miR-27a*
miR-21 miR-181b miR-218 miR-373 miR-16* miR-27b
miR-25 miR-184** miR-498 miR-23a miR-29a*
miR-26a* miR-187 miR-503 miR-23b miR-29b*
miR-27a* miR-191 miR-184** miR-26a* miR-30a-5p
miR-29a* miR-195* miR-198** miR-92* miR-30b
miR-29b* miR-196 miR-302c miR-99 miR-30c*
miR-30c* miR-197 miR-345 miR-103 miR-100
miR-32 miR-198** miR-491 miR-125a miR-141
miR-34a miR-199 miR-513 miR-125b miR-148a
miR-92* miR-203 miR-143 miR-205
miR-93 miR-206 miR-145 
miR-95 miR-214 miR-195* 




*Reverse differential expression; **identical expression.
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This manipulation significantly stimulated the growth of these cell
lines in the absence of androgens and induced a 3-fold increase in
the S-phase fraction in LNCaP cells compared to controls. On the
contrary, repression of miR-125b activity in LNCaP-cds1 cells by
transfection with anti-miR-125b significantly inhibited cell growth
and induced a 54% reduction of the S-phase fraction and a signif-
icant increase of sub-G1 cells, relative to controls. These results
demonstrated that miR-125b is associated with the AI growth and
survival of CaP cells [33].
miR-126* 
In human cells, miR-126* maps to a specific intron of the Egfl7
gene on chromosome 9, and is consequently co-expressed with
the Egfl7 transcript. Recently, Musiyenko and colleagues [40]
observed that due to poor Egfl7 expression in LNCaP cells, miR-
126* was undetectable. The lack of miR-126* in CaP cells sug-
gested that this miRNA may act as a tumour suppressor. They
thus evaluated the effect of increasing miR-126* expression on
the phenotype of LNCaP cells. It was found that ectopic expres-
sion of miR-126* resulted in a significant reduction in the migra-
tion and invasiveness of LNCaP cells, which supported the notion
that loss of miR-126* expression could contribute to the malig-
nant phenotype of CaP cells.
miR-146a 
As discussed above, Lin et al. [32] found that miR-146a was
down-regulated in AI CaP cells, suggesting a tumour-inhibitory
function for this miRNA. To validate this function of miR-146a,
miR-146a was transfected into PC3 cells, which do not express
this miRNA. Ectopic expression of miR-146a in PC3 cells markedly
reduced their proliferation rate. Furthermore, miR-146a-express-
ing cells displayed neither invasive nor metastatic activity. These
data suggest that miR-146a is a tumour suppressor that inhibits
PC3 cell growth.
miR-221/222 
In a recent study, Galardi et al. [41] found that aggressive PC3
cells highly expressed miR-221 and miR-222, which are tran-
scribed in tandem from a gene cluster located on chromosome X.
However, these two miRNAs were down-regulated in both AR-
positive LNCaP and 22Rv1 cell lines that are less aggressive rela-
tive to AR-negative PC3 cells. To study the biological significance
of miR-221/222, LNCaP cells were stably transfected with miR-
221 and miR-222 alone or in combination and their effects on cell
growth and colony formation in soft agar were evaluated. It was
observed that ectopic expression of the miRNAs induced a >2-fold
increase in growth rate and a 3–4-fold increase in the colony for-
mation in miRNA-transfected LNCaP cells compared to empty
plasmid-transfected cells. Expression of these miRNAs also stim-
ulated a significant increase in the fraction of cells in S phase.
Accordingly, antisense-mediated inhibition of miR-221/222 in PC3
cells strongly reduced (i.e. 4.5-fold) the number of the colonies
growing in soft agar. These results suggest that miR-221 and
miR-222 may contribute to the growth and progression of CaP.
In addition to these five CaP-related miRNAs described above,
let-7c may be involved in the pathogenesis of CaP. Overexpression
of let-7c has been reported in CaP cells [29, 33]. Although the
function of the miRNA in CaP remains to be defined, we recently
observed that the miRNA is significantly up-regulated in LNCaP
cells exposed to interleukin-6 (IL-6) compared to the LNCaP con-
trol. Since IL-6 plays an important role in androgen-independent
growth of CaP cells [42], our finding suggests that let-7c may be
related to IL-6-induced CaP progression.
In summary, only a few CaP-related miRNAs have been
characterized for their functional significance. These miRNAs may
contribute to the pathogenesis of CaP through oncogenic activities
or tumour suppressive functions, respectively. That being said,
further investigations are warranted to identify CaP-related
miRNAs and to better define the breadth and mechanisms of their
biological activities. This will likely provide novel insights into the
molecular alterations associated with this disease and potential
opportunities for therapeutic interventions of CaP.
Identification of targets of prostate
cancer-related miRNAs
miRNAs are powerful repressors of gene expression, and their
impact on the growth of CaP cells depends on the functions of
downstream targets they suppress. For example, accumulation of
an onco-miRNA that targets the mRNAs of tumour suppressors
would result in reduction of the tumour suppressors. In contrast,
decreased expression of a ts-miRNA that targets the mRNAs of
proto-oncogenes could lead to excessive amounts of the onco-
genic proteins [9]. The net outcome of both pathways would be an
imbalance of the activities of tumour suppressor genes and onco-
genes. Therefore, to better understand how miRNAs contribute to
CaP’s pathogenesis, the mRNA targets of each CaP-related miRNA
must be identified. The fact that a single miRNA can inhibit the
expression of many mRNA targets and a particular mRNA may be
silenced by multiple different miRNAs certainly complicates the
validation of true mRNA targets in CaP. Therefore, identification of
miRNA targets represents a great challenge.
While various methods have been described for discovering
miRNA-targeted mRNAs [43–46], there is no clear agreement as
to which procedure should be utilized to determine that a given
mRNA is a target of a specific miRNA [43]. Of these methods,
bioinformatic prediction followed by experimental validation is the
most commonly used strategy for identification of miRNA targets.
Many computational algorithms are used to predict miRNA
J. Cell. Mol. Med. Vol 12, No 5A, 2008
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targets, however, TargetScan (http://www.targetscan.org), miRanda
(http://microrna.sanger.ac.uk) and PicTar (http://pictar.bio.nyu.edu)
are considered to be relatively sensitive target prediction algo-
rithms [47]. They predict miRNA targets based on various param-
eters, including the degree of base complementarity between the
seed sequences of a given miRNA and the 3-UTRs of its mRNA
targets, and the thermodynamic stability of the predicted
miRNA:mRNA complex. Presently, all mRNA targets of currently
identified miRNAs have been predicted and are available online.
For each miRNA, the number of mRNA targets predicted by differ-
ent algorithms is highly variable and ranges from a handful to
more than 800 transcripts [47]. The accurate selection of putative
targets for experimental validation is a challenge. Iorio et al. [48]
and Kuhn et al. [43] deemed that if a target is predicted using at
least two of the three different algorithms, it should be considered
as a good candidate for experimental validation. This rule has been
used by several groups for identification of miRNA targets [36, 48,
49]. Compared to other target-prediction approaches like microar-
ray-based analyses, the bioinformatic strategy is very simple,
rapid and less expensive. A biochemical validation of computer-
predicting miRNA targets is highly desirable. Kuhn et al. [43] rec-
ommended that four criteria should be met before a computer-
predicting miRNA target is considered as a true target. First, a
reporter construct containing the 3’-UTR of a predicted miRNA
target cloned distal to firefly luciferase should exhibit decreased
luciferase activity when transfected into a cell expressing the cog-
nate miRNA. Second, if an miRNA is able to repress the expres-
sion of its biological target, the miRNA and its target mRNA must
be co-expressed. Third, a given miRNA must have a predictable
effect on target protein expression. That is, transient transfection
of the miRNA in a cell type known to express the putative target
should decrease the expression of this target; conversely, repres-
sion of miRNA activity using specific anti-miRNA will increase the
target expression. Fourth, if a given target has a known function
and is suspected of being specifically regulated by a given miRNA,
treatment of the cells with the miRNA should result in a corre-
sponding alteration of the target’s function.
Several miRNA targets have been validated in CaP (Table 2).
They are E2F1 [39], Bak1 [33], SLC45A3 (solute carrier family 45,
member 3) [40], ROCK1 [32] and p27Kip1 [41]. E2F1, Bak1 and
p27Kip1 are growth-inhibitory and are direct targets of miR-20a,
miR-125b and miR-221/222, respectively. Although E2F1 can pro-
mote cell cycle progression in many cellular contexts, overexpres-
sion of E2F1 promotes apoptosis in PC3 cells [39]. Bak1, a Bcl-2
family member, also functions as a pro-apoptotic regulator by
antagonizing the function of anti-apoptotic Bcl-2 family proteins.
In previous studies, Bak1 and Bax were reported to modulate
apoptotic signalling in CaP synergistically. Knockdown of Bak1
and Bax completely prevented apoptosis induced by a variety of
biological molecules and chemical compounds [50, 51]. Loss of
Bak1 expression has also been reported to be associated with the
progression of CaP. In a clinical study, Bak1 was detected in
77.5% primary and untreated localized CaP, but in only 33% hor-
mone-refractory CaPs [52]. Decreased or absent expression of
p27Kip1, a cyclin-dependent kinase inhibitor, was associated with
high tumour grade and poor prognosis of CaP [53]. In CaP cells,
both SLC45A3 and ROCK1 are proliferation-related genes and
their expression is repressed by miR-126* and miR-146a, respec-
tively. SLC45A3, also called prostate cancer-associated protein 6
(PCANAP6) and prostein, is a recently described molecule and is
expressed in a prostate-specific manner [54, 55]. This molecule is
an important determinant of motility and invasiveness of CaP cells
[40]. ROCK1 is a Rho-activated protein kinase that is highly
involved in AI growth and metastasis of PC3 cells [56]. Active
ROCK1 increases phosphorylation of myosin light chain and sub-
sequent contraction of actin-myosin complex, which might
enhance cancer migration and metastasis [57]. Active ROCK1 can
also promote the activation of PI3K [56], leading to activation of
pro-survival signalling via the Akt/mTOR/eIF4E pathway, demon-
strated to promote malignant transformation and drug resistance
in hormone-refractory CaP [58].
In the above studies, only one target per CaP-related miRNA
was identified. Identification of a single target may not reflect the
entire biological function of an miRNA, since a single miRNA
species can target multiple mRNAs for degradation or translation-
al repression. For example, miR-125b down-regulates the pro-
apoptotic regulator Bak1. While repression of miR-125b with anti-
miR-125b induced apoptosis in CaP cells [33], siRNA-mediated
knockdown of Bak1 expression did not result in significantly
increased proliferation, suggesting that silencing of multiple targets
Table 2 Targets of CaP-related miRNAs and their function
CaP-related miRNA Function Targets and function Methods for validating targets Ref.
miR-20a oncomiRNA E2F1-3: cell cycle regulator, pro-apoptosis reporter assay, WB [39]
miR-125b oncomiRNA Bak1: pro-apoptotic regulator microarray, reporter assay, WB [33]
miR-126* ts-miRNA SLC45A3: related to prostate malignancy tansfection, PCR, WB [40]
miR-146a ts-miRNA ROCK1: myosin phosphorylation; PI3K activation tansfection, NB, WB [32]
miR-221/222 oncomiRNA p27Kip1: inhibition of cell cycle tansfection, reporter assay, WB [41]
oncomiRNA, oncogenic miRNA, ts-miRNA, tumour-suppressor miRNA; WB, Western blotting, NB, Northern blotting.
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is required to mimic the function of miR-125b. Therefore, in order
to elucidate the biological significance of miR-125b, additional tar-
gets of this miRNA must be identified. We have identified another
miR-125b target, SGPL1 that is involved in tumour suppressor
and cancer-surveillance pathways [59]. Further identification of
miR-125b targets in CaP cells will lead to an enhanced under-
standing of the role of miR-125b in the development and progres-
sion of CaP. Identification and functional validation of CaP-related
miRNA targets is providing new insights into the molecular mech-
anism underlying the oncogenic effects of miRNAs. Although val-
idation of the targets is a daunting task, it is indeed worthwhile and
necessitated by the goal to achieve a precise and comprehensive
understanding of miRNA function.
Regulation of miRNAs in
prostate cancer
Limited information is available regarding the regulation of the
expression of miRNAs. Studies have shown that factors that affect
the expression of protein-encoding genes can disrupt the regula-
tion of miRNAs in cancer cells, including miRNA gene copy num-
ber (i.e. gain or loss), mutations of the precursor miRNAs, histone
deacetylation and hypermethylation of miRNA promoters, and
aberrant miRNA processing. Saito et al. [60] demonstrated that
treatment of human tumour cells with demethylating agents high-
ly induced the expression of miR-127. Their results suggested that
epigenetic silencing serves as one mechanism of miRNA regula-
tion in cancer cells. In addition, there is evidence showing that
aberrantly expressed miRNAs are regulated indirectly through
their processing enzymes, including RNA polymerase II and two
nuclear RNases (Drosha and Dicer). For instance, Thomson et al.
[61] reported that altered Drosha function regulates the abun-
dance of miRNAs and Chiosea et al. [62] observed an increased
expression of Dicer and most of its partners in metastatic prostate
tumours. The up-regulation of Dicer may be associated with a
global increase of miRNA expression in CaP. Since these enzymes
regulate miRNA expression in a generalized, non-specific manner,
the participation of additional factors is most likely required for the
regulation of the cellular levels of individual miRNAs. Accordingly,
studies have shown that transcriptional factors involved in mRNA
transcription also contribute to miRNA transcriptional regulation.
An example is tumour suppressor p53 that transcriptionally acti-
vates the expression of miR-34 [63, 64]. Additionally, the tran-
scription factors E2F1–3 can directly bind to the promoter of the
miR-17-92 cluster and induce the expression of seven miRNAs
including miR-20a. The miRNA in turn binds to the 3’-UTRs of
E2F1-3 transcripts and represses their translation, thereby estab-
lishing an autoregulatory feedback loop between E2F1-3 and
miR-20a [39].
The role(s) of nuclear steroid hormone receptors in the tran-
scriptional regulation of miRNA expression is virtually unknown.
However, several lines of evidence suggest that the AR may be
involved in the regulation of the expression of miRNAs. First,
chromatin immunoprecipitation (ChIP)-on-Chip analysis identi-
fied and mapped the locations of 90 AR-binding sites along chro-
mosomes 21 and 22 in LNCaP cells [65]. Fifty-four (62%) of
these sites were found to be very far from transcription start sites
of androgen-regulated genes (e.g. 500–8000 kb) while only 
34 (38%) sites are located within 500 kb [65]. Since not all these
distant AR-binding sites act as transcriptional enhancers of
neighbouring protein-encoding genes, some of these sites may
have other functions. Analysis of these ChIP-on-Chip data
revealed that in the chromosome 21 an AR-binding site is locat-
ed within 83 kb from miR-802, while the site is 995 kb far from
the transcriptional start site of the neighbouring MORC3 gene
that is regulated by androgen. Similarly, in chromosome 22 an
AR-binding is located within 49 kb from miR-130b and miR-
301b, but it is 2241 kb away from the androgen-regulated GSTT2
gene [65]. Since the oestrogen receptor (ER) can bind to the dis-
tal (144 kb) ER binding site to regulate the transcription of target
gene [66], it is possible that the AR-binding sites nearby miR-
802, miR-130b and miR-301b might drive the expression of these
miRNAs. Secondly, global gene expression profiles of androgen-
treated CaP cells have identified a large number of androgen-reg-
ulated genes. In LNCaP cells, for example, approximately 1.5% to
4.3% of the transcriptome are either directly or indirectly regulat-
ed by androgen [67]. However, only a small number of genes
have been confirmed to be directly regulated by the AR [68]. A
majority of these genes are believed to be indirectly regulated by
androgen-AR signalling. How androgen-AR signalling indirectly
regulates gene expression has not been clearly delineated. It is
possible that there is an androgen-AR-miRNA-target gene-sig-
nalling pathway in CaP cells. Confirmation of this pathway may
provide a mechanistic explanation for androgen-mediated regula-
tion of gene expression. Thirdly, Porkka et al. [37] found that
miRNA expression was associated with the AR status in CaP cell
lines and xenografts, suggesting that androgens may regulate the
expression of a subset of miRNAs. In another report, transfection
of the AR into PC3 cells induced the differential expression of 
11 miRNAs compared to AR-negative PC3 cells [32].
Our recent results provided direct evidence that androgen-AR
signalling regulates the expression of certain miRNAs. We evalu-
ated the effect of androgens on the expression of miR-125b in AR-
positive CaP cell lines using locked nucleic acid-probe-mediated 
in situ hybridization (LNA-ISH) analysis. In the absence of andro-
gens, reduced levels of miR-125b were detected in these cell lines
while androgen treatment stimulated a marked increase in miR-
125b. In addition, transfection of the AR into AR-negative prostate
epithelial cells followed by treatment with androgen also increased
the abundance of miR-125b. Since a typical TATA box and poten-
tial androgen responsive elements (AREs) were identified in the
5-region of miR-125b-2, we tested the possibility that this was a
direct transcriptional target of the AR. ChIP analysis demonstrat-
ed that the AR was recruited to the 5 DNA region of the miR-
125b-2 locus in an androgen-dependent manner. These results
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strongly suggest that androgen-AR signalling mediates the
regulation of miR-125b-2 in CaP cells [33].
Potential application of miRNAs in
prostate cancer
Although the utilization of miRNAs as cancer biomarkers has not
yet been implemented in clinical practice, studies have demon-
strated that the expression of several miRNAs is different in
benign and malignant prostate tissues and in different stages of
disease [20, 36, 37]. As a result, CaP-related miRNAs represent
attractive novel biomarkers for clinical CaP as they might be
potentially useful for diagnosis, as prognostic indicators, and in
monitoring response to treatment. The cellular levels of miRNAs
in clinical CaP samples can be measured using various RNA detec-
tion approaches. Global miRNA expression profiling is a powerful
tool and can be used to identify the aberrant expression of
miRNAs. However, employing this approach as a diagnostic tool
for clinical cases of CaP would not be practical due to the hetero-
genecity of clinical CaP samples. LNA-modified miRNA probes
markedly increase hybridization affinity to miRNAs compared to
traditional RNA or DNA probes. LNA-ISH has been employed for
detection of miRNA levels in formalin-fixed archival human cancer
samples in which miRNAs remain largely intact and remarkably
stable [33, 69]. Therefore, once certain miRNAs are confirmed as
useful biomarkers in CaP, LNA-ISH analysis of their expression
can be readily adapted to clinical practice.
Since miRNAs act as either oncogenes or tumour suppressor
genes, they have significant potential as therapeutic targets for
cancer treatment [70]. In recent studies, repression of CaP-relat-
ed oncogenic miRNAs (miR-20a, miR-125b and miR221/222)
using specific anti-miRNAs resulted in a significant increase in
cell death [33, 39,41]. These findings hold promise that CaP-
related miRNAs may eventually be exploited as therapeutic tar-
gets. The miRNA-based therapeutic manipulation can be carried
out by the utilization of an antagonistic miRNA that specifically
inhibits an oncogenic miRNA and/or the employment of a syn-
thetic miRNA that specifically targets oncogenic mRNAs. An
advantage of an miRNA-based therapeutic strategy over the cur-
rent single gene therapy is the capacity of an miRNA to target
multiple downstream effectors. As a result, miRNA-mediated tar-
geting therapy may be more effective than traditional single gene
therapy. However, there is a long way to go before miRNAs can
be used for CaP treatment. To achieve this goal, several key
obstacles need to be overcome. First, CaP-related miRNAs that
silence critical tumour suppressors or activate key oncogenes
need to be identified. Only when these important miRNAs are
identified and their functions elucidated, can we manipulate them
for therapeutic benefit in a rational manner. A second major chal-
lenge is presented by the methods required to deliver a specific
miRNA into solid CaP tissue and maintain continuous activity;
this is common to many nucleic acid-based therapeutic
approaches. The recent finding that Pol II promoter-driven
expression of an shRNA directed against miR-30 may provide a
potential way to overcome this problem [71].
Conclusion
From the foregoing discussion, it is evident that we have already
learned a great deal about the function and role of miRNAs in CaP
cells. Knowledge of these small RNAs can significantly improve
our understanding regarding the pathogenesis of this disease. It is
clear that some miRNAs are implicated in this cancerous disease
process, which results in augmented expectation that miRNAs will
be useful targets for clinical practice. However, the study of
miRNAs is a relatively new area in CaP. Many aspects of these
small RNA molecules remain to be clarified, including their abun-
dance in different disease stages, their actual in vivo functions,
regulation of CaP-related miRNA expression and potential clinical
applications. It is expected that the current CaP-related miRNA
database will be updated with additional aberrantly expressed
miRNAs. Functional characterization of these miRNAs remains a
great challenge and a more efficient biochemical strategy is
desired to precisely identify the key targets of each CaP-related
miRNA. Elucidation of the signal transduction pathways that reg-
ulate the expression of CaP-related miRNAs is another significant
challenge. If an androgen-AR-miRNA-target signal pathway is ver-
ified to exist, this would represent an important contribution to our
understanding of AR signalling and would help elucidate the
mechanisms regarding AI growth of CaP cells. In this regard, it is
fair to have optimism as scientists historically have risen to these
challenges.
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